Ftse Mib
35.355,87
0,58%
DAX
18.869,36
0,78%
S&P 500
5.308,15
1,17%
NASDAQ
16.736,22
1,36%
Bitcoin
65.909,17
7,09%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Mesoblast Limited (MESO) Mesoblast Limited (MESO) Notizie

MESO

Mesoblast (MESO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MESO
DataOraFonteTitoloSimboloCompagnia
30/04/202403:05GlobeNewswire Inc.Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024NASDAQ:MESOMesoblast Limited
26/03/202414:25AllPennyStocks.comFDA Commentary Sends Biotech Soaring During Premarket HoursNASDAQ:MESOMesoblast Limited
26/03/202403:34GlobeNewswire Inc.United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
14/03/202400:30GlobeNewswire Inc.Mesoblast Successfully Completes Placement and Accelerated Entitlement OfferNASDAQ:MESOMesoblast Limited
11/03/202400:54GlobeNewswire Inc.United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)NASDAQ:MESOMesoblast Limited
28/02/202423:57GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023NASDAQ:MESOMesoblast Limited
26/02/202413:00GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
15/02/202401:46GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
01/02/202403:34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
31/01/202403:13GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023NASDAQ:MESOMesoblast Limited
19/01/202401:28Dow Jones NewsMesoblast Gets FDA's Special Pediatric Designation for Revascor Heart TreatmentNASDAQ:MESOMesoblast Limited
19/01/202400:36GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
05/01/202403:57Edgar (US Regulatory)Form F-6 POS - Post-effective amendments for immediately effective filingNASDAQ:MESOMesoblast Limited
27/11/202300:56GlobeNewswire Inc.Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
22/11/202319:35AllPennyStocks.comBiotech Shares Soar Following Major AnnouncementNASDAQ:MESOMesoblast Limited
22/11/202300:32GlobeNewswire Inc.Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHDNASDAQ:MESOMesoblast Limited
31/10/202301:04GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023NASDAQ:MESOMesoblast Limited
26/09/202312:18GlobeNewswire Inc.Jane Bell AM Appointed Chair of Mesoblast Audit and Risk CommitteeNASDAQ:MESOMesoblast Limited
21/09/202309:30GlobeNewswire Inc.Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL ApprovalNASDAQ:MESOMesoblast Limited
06/09/202312:42Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MESOMesoblast Limited
31/08/202301:07GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023NASDAQ:MESOMesoblast Limited
04/08/202315:03Dow Jones NewsMesoblast ADSs Plunge Premarket on Latest FDA RejectionNASDAQ:MESOMesoblast Limited
04/08/202302:10GlobeNewswire Inc.Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in ChildrenNASDAQ:MESOMesoblast Limited
31/07/202302:31GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023NASDAQ:MESOMesoblast Limited
06/06/202314:46Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
05/06/202302:21GlobeNewswire Inc.Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory RoleNASDAQ:MESOMesoblast Limited
30/05/202312:06Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MESOMesoblast Limited
26/05/202301:28GlobeNewswire Inc.Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023NASDAQ:MESOMesoblast Limited
28/04/202303:00GlobeNewswire Inc.Appendix 4C Quarterly Activity ReportNASDAQ:MESOMesoblast Limited
26/04/202302:47GlobeNewswire Inc.Mesoblast Completes Private PlacementNASDAQ:MESOMesoblast Limited
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MESO

La tua Cronologia

BIT
UI661A
Unicredit Bank
BMF
BGIG18
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network